Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

September 04, 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

August 26, 2018

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

September 08, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

August 29, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Conference News ESC 2014

FAME 2: FFR-Guided PCI Continues on Same Trajectory from 1 to 2 Years

September 02, 2014

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

September 01, 2013

News Conference News ESC 2013

PRAMI: Strong Showing for Complete Revascularization in Acute STEMI Patients

September 01, 2013

News Conference News ESC 2012

FAME 2: PCI Bests Medical Therapy in Stable Patients with Proven Ischemia

August 28, 2012

News Conference News

Halting Clopidogrel in First Year Following Acute MI Hazardous

September 01, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.